Patient and stakeholder engagement
toxicity, cancer, prostate cancer
CANCER, PROSTATE CANCER
At the start of the study, a patient and stakeholder advisory board was formed consisting of a survivor of prostate cancer, a patient advocate and leader of a local prostate cancer advocacy and education group, a urologist, a community engagement leader at the cancer center and expert on prostate cancer disparities, and an oncologist with expertise in financial toxicity. This team met monthly throughout the duration of the project to advise on the study design, intervention adaptation to include cost‐related information, outcome measures selected, social service organisations and personnel for cost‐related referrals, data interpretation, and dissemination of study findings.